Alexion Pharmaceuticals, Inc.

Enrollment initiated in pivotal phase III PRIMO-CABG-2 trial

Published in Health Insurance Law Weekly, August 22nd, 2004

Alexion Pharmaceuticals, Inc., (ALXN) announced that they and their collaboration partner for pexelizumab, Procter & Gamble Pharmaceuticals, Inc., (P&GP), have initiated patient enrollment for the pivotal phase III PRIMO-CABG-2 trial in patients undergoing coronary artery bypass graft surgery.

Alexion reported on June 14 that they, together with P&GP, had reached agreement with the U.S. Food & Drug Administration (FDA) on the design for the PRIMO-CABG-2 study under the Special Protocol Assessment (SPA) process. It is expected that, if successful, this trial will complete the filing package that will serve as the primary basis of review for the approval of a Biologics...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly

Source: Health Insurance Law Weekly (2004-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry